GTP-0805, when combined with tamoxifen and delivered orally, resulted in a 78 per cent reduction in breast tumour growth compared to a 21 per cent reduction when tamoxifen alone was administered
Phosphagenics has announced the results of its pre-clinical trial with its patented anti-cancer agent GTP-0805.
The results demonstrated that GTP-0805 given orally in combination with tamoxifen, inhibited the rate of tumour growth by more than three times the rate observed when compared to tamoxifen alone.
Conducted at Monash University, Melbourne, Australia, the trial was designed to examine the potential anti-tumour properties of various doses of oral GTP-0805, either given alone, or in combination with tamoxifen, in a recognised pre-clinical model for breast cancer.
The study showed that GTP-0805, delivered orally in combination with tamoxifen, resulted in a 78 per cent reduction in breast tumour growth compared to a 21 per cent reduction seen when tamoxifen alone was administered.
In addition, GTP-0805 appeared to promote the earlier anti-tumour activity of tamoxifen.
Esra Ogru, executive director of research and development at Phosphagenics, said the pre-clinical trial results suggest that GTP-0805 can improve the effectiveness of tamoxifen, a well established anti-cancer agent.
"The primary objectives of this trial were to determine whether there were any dose-dependent reduction in tumour growth, and whether GTP-0805 protected against the onset of tumour growth.
This pre-clinical study clearly achieved both these objectives," Ogru said.
"Breast cancer is one of the most common cancers in women and is a leading cause of cancer-related death among those aged between 35 and 54 years of age.
"To be developing a product that has the potential to enhance the activity of tamoxifen, one of the world's leading breast cancer treatments, is certainly an exciting development," she added.
Phosphagenics managing director Harry Rosen said: "This result provides another significant opportunity for Phosphagenics to expand its pipeline and is another key milestone in Phosphagenics' strategy to discover new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.
"The potential market for GTP-0805, both as an adjunct cancer therapy to tamoxifen and possibly to other cancer medications, could be significant.
"Phosphagenics will now investigate the combination of GTP-0805 with other cancer drugs and in other forms of cancer," he said.
